Risk factors for anterior capsule contraction syndrome with polypropylene or poly(methyl methacrylate) haptics.
OBJECTIVE
To determine the effect of haptic composition on the development of anterior capsule contraction syndrome (CCS) requiring neodymium: YAG anterior capsulotomy.


METHODS
Ophthalmology practice in Lancaster, Pennsylvania, USA.


METHODS
This retrospective study covered a 30 month period during which 1 surgeon discontinued implanting AMO SI-30NB intraocular lenses (IOLs) with polypropylene haptics (n = 216) in favor of SI-40NB IOLs with poly(methyl methacrylate) (PMMA) haptics (n = 127). The transition was motivated by the suspicion that the PMMA haptics would maintain the capsulorhexis opening better and reduce the need for an anterior capsulotomy.


RESULTS
Three eyes with SI-30NB IOLs (1.4%) required anterior capsulotomies; 2 eyes had preoperative pseudoexfoliation syndrome and required the capsulotomy within 3 months of surgery. Three eyes with SI-40NB IOLs (2.4%) required anterior capsulotomies within 4 months; 2 eyes had preoperative pseudoexfoliation syndrome and 1 had traumatic zonular weakness. The incidence of anterior capsulotomy did not differ significantly between the 2 IOL populations (P > .5), although preoperative pseudoexfoliation syndrome was a significant risk factor in both groups (P < .005).


CONCLUSIONS
The polypropylene haptics of the SI-30NB IOL and the PMMA haptics of the SI-40NB IOL did not differ significantly in their ability to prevent CCS requiring anterior capsulotomy. Regardless of IOL haptic composition, eyes with preoperative zonular weakness associated with pseudoexfoliation syndrome or ocular trauma can develop CCS within 3 months of surgery and should, therefore, be followed closely in the early postoperative weeks to minimize the sequelae of anterior capsule fibrosis.
Gallagher
S P
SP
Eye Specialists of Lancaster, Pennsylvania 17601, USA.
Pavilack
M A
MA
D000368:Aged; D000369:Aged, 80 and over; D000869:Anterior Eye Segment; D019923:Capsulorhexis; D005260:Female; D006801:Humans; D053685:Laser Therapy; D007903:Lens Capsule, Crystalline / Q000473:pathology* / Q000601:surgery; D007905:Lens Diseases / Q000209:etiology* / Q000601:surgery; D019654:Lens Implantation, Intraocular; D007910:Lenses, Intraocular / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D019904:Polymethyl Methacrylate; D011126:Polypropylenes; D012307:Risk Factors; D013577:Syndrome
D011126:Polypropylenes; D019904:Polymethyl Methacrylate